Matthew Jorgensen to Influenza Vaccines
This is a "connection" page, showing publications Matthew Jorgensen has written about Influenza Vaccines.
Connection Strength
0.524
-
Holbrook BC, Aycock ST, Machiele E, Clemens E, Gries D, Jorgensen MJ, Hadimani MB, King SB, Alexander-Miller MA. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. Immunology. 2018 03; 153(3):357-367.
Score: 0.140
-
Holbrook BC, D'Agostino RB, Tyler Aycock S, Jorgensen MJ, Hadimani MB, Bruce King S, Alexander-Miller MA. Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6months in a nonhuman primate neonate model. Vaccine. 2017 10 27; 35(45):6137-6142.
Score: 0.139
-
Holbrook BC, Kim JR, Blevins LK, Jorgensen MJ, Kock ND, D'Agostino RB, Aycock ST, Hadimani MB, King SB, Parks GD, Alexander-Miller MA. A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model. J Immunol. 2016 07 15; 197(2):555-64.
Score: 0.127
-
Kim JR, Holbrook BC, Hayward SL, Blevins LK, Jorgensen MJ, Kock ND, De Paris K, D'Agostino RB, Aycock ST, Mizel SB, Parks GD, Alexander-Miller MA. Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates. J Virol. 2015 Jul; 89(14):7291-303.
Score: 0.118